Investigating the role of Interferon E in pancreatic cancer treatment
Interferon E as a Tumor Suppressor and Potential Therapeutic in Pancreatic Cancer
This study is looking at how a gene called Interferon E might help fight pancreatic cancer by stopping tumors from growing and spreading, and it will also test if using this gene in a special way could boost the immune system to better attack the cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11070938 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific gene, Interferon E, can act as a tumor suppressor in pancreatic cancer. The study will explore the effects of deleting this gene in mouse models of pancreatic ductal adenocarcinoma (PDAC) to see how it influences tumor growth, metastasis, and the immune response. Additionally, the research will test the potential of using recombinant Interferon E as a therapeutic option to enhance immune surveillance against tumors. By examining these factors, the research aims to uncover new strategies for improving treatment outcomes for patients with pancreatic cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with specific genetic profiles related to the 9p21.3 deletion.
Not a fit: Patients with other types of cancer or those without the relevant genetic markers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that enhance the immune system's ability to fight pancreatic cancer.
How similar studies have performed: Previous research has shown promising results in targeting immune responses in cancer, suggesting that this approach could be effective, although the specific focus on Interferon E in pancreatic cancer is relatively novel.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Del Priore, Isabella — Sloan-Kettering Inst Can Research
- Study coordinator: Del Priore, Isabella
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.